Literature DB >> 17239100

Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.

Emilio Perucca1, Fiorenzo Albani, Giuseppe Capovilla, Bernardo Dalla Bernardina, Roberto Michelucci, Gaetano Zaccara.   

Abstract

The availability of generic products of antiepileptic drugs (AEDs) has been increasing in recent years. In view of the importance of the issue, the Italian League against Epilepsy (LICE) set up an ad hoc working group whose task was to assess available evidence on the efficacy and safety of generic AEDs in the treatment of epilepsy and to produce recommendations on their use. A careful review of the literature revealed no adequately powered randomized controlled trials that assessed the risk/benefit ratio of generic substitution. Although there have been reports of loss or worsened seizure control, or appearance of adverse events, following the switch from brand products to generics, a critical assessment of the evidence generally does not allow us to establish a cause-effect relationship between the switch and a change in clinical status. Overall, the working group concluded that generic AEDs meeting current regulatory criteria for bioequivalence represent a valuable choice in the management of epilepsy by allowing a substantial reduction of treatment costs, particularly in patients initiating monotherapy or adjunctive treatment and in those with persistent seizures. The working group considered that in patients who achieved seizure freedom a modest change in plasma drug levels, which may occasionally occur even after substitution of products that meet bioequivalence criteria, could in rare cases lead to seizure breakthrough. Therefore, generic substitution is not recommended in patients who achieved seizure remission. Switches between a particular generic and another generic should also be preferably avoided. Finally, sustained-release AED formulations should not be used interchangeably with immediate-release brand or generic products. Patients need to be informed about the stringent criteria that currently govern the approval of generic products and about the implications of the use of generic AEDs, and their opinion should be taken into consideration at the time of prescribing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17239100     DOI: 10.1111/j.1528-1167.2006.00871.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  16 in total

1.  [Change from original preparations to generics. A case example with oxcarbazepine].

Authors:  G Hagemann; J Zinke; M Fuchs; O W Witte
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

2.  The Controversy over Generic Antiepileptic Drugs.

Authors:  Susan J Shaw; Adam L Hartman
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

Review 3.  Requirements for generic antiepileptic medicines: a clinical perspective.

Authors:  Eugen Trinka; Günter Krämer; Martin Graf
Journal:  J Neurol       Date:  2011-06-11       Impact factor: 4.849

4.  [Changing lamotrigine preparations in epilepsy patients. Experiences of a university epilepsy outpatient centre].

Authors:  A Carius; A Schulze-Bonhage
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

5.  Clinical experience with generic levetiracetam in people with epilepsy.

Authors:  Siresha Chaluvadi; Sharon Chiang; Larry Tran; Corey E Goldsmith; David E Friedman
Journal:  Epilepsia       Date:  2011-03-22       Impact factor: 5.864

6.  Refilling and switching of antiepileptic drugs and seizure-related events.

Authors:  J J Gagne; J Avorn; W H Shrank; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2010-07-14       Impact factor: 6.875

7.  Generic antiepileptic drugs.

Authors:  Susan J Shaw; Gregory L Krauss
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

Review 8.  Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Margaret R Stedman; Ellen J Bubrick; Joshua J Gagne; Alexander S Misono; Joy L Lee; M Alan Brookhart; Jerry Avorn; William H Shrank
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

9.  Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

Authors:  Maria Stella Vari; Francesca Pinto; Elisabetta Mencaroni; Giovanna Giudizioso; Carlo Minetti; Angela La Neve; Tiziana Francavilla; Marta Piccioli; Salvatore Striano; Luigi del Gaudio; Pierangelo Tovo; Pasquale Striano; Alberto Verrotti
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

10.  Substitution of anticonvulsant drugs.

Authors:  Bernhard J Steinhoff; Uwe Runge; Otto W Witte; Hermann Stefan; Andreas Hufnagel; Thomas Mayer; Günter Krämer
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.